Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-019-03365-y
Abstract: Background and purpose Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas, with an average survival rate of 15 months after diagnosis. More than 90% of all GBMs have activating mutations in the MAPK/ERK… read more here.
Keywords: delivered via; binimetinib mek162; polymeric nanocarriers; mek162 delivered ... See more keywords
Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-17-0480
Abstract: Glioblastoma (GBM) is a highly aggressive and lethal brain cancer type. PI3K and MAPK inhibitors have been studied preclinically in GBM as monotherapy, but not in combination with radiotherapy, which is a key component of… read more here.
Keywords: cell; glioblastoma; gbm; treatment ... See more keywords
A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.290
Abstract: 290Background: Activating mutations in the RAS/RAF/MEK/ERK signaling pathway are commonly found in ABC. MEK162 is an oral, selective small molecule inhibitor of MEK1/2; single agent activity of MEK162 in ABC has previously been observed. Preclinical… read more here.
Keywords: phase; mek162 combination; trial mek162; abc ... See more keywords